RIGEL PHARMACEUTICALS INC

For the period ended Dec 31, 2024. Filed Mar 4, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 4, 2025

RIGL$42.05+6.1%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Statements of Cash Flows

(In thousands)


· · Year Ended December 31,
· · 2024 · 2023 · 2022
Operating activities
Net income (loss)	$17,485	$(25,091)	$(58,573)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Stock-based compensation expense	12,393	8,806	12,385
(Gain) loss on sale and disposal of fixed assets	(79)	266	(138)
Depreciation and amortization	2,228	1,238	998
Non-cash interest expense	—	—	682
Net amortization of discount on short-term investments and term loans	(709)	(479)	(63)
Changes in assets and liabilities:
Accounts receivable, net	(11,065)	9,770	(24,848)
Inventories	764	1,172	(2,377)
Prepaid and other current and non-current assets	(3,440)	2,054	(513)
Right-of-use assets	615	1,069	7,773
Accounts payable	(3,803)	(366)	3,788
Accrued compensation	1,463	(190)	(1,824)
Accrued research and development	560	(4,195)	(2,676)
Revenue reserves and refund liability	10,756	3,539	4,230
Other accrued liabilities	4,995	(1,151)	1,709
Lease liability	(692)	(1,128)	(8,546)
Deferred revenue	—	(14)	(1,227)
Other current and long-term liabilities	—	(1,043)	(4,538)
Net cash provided by (used in) operating activities	31,471	(5,743)	(73,758)
Investing activities
Maturities of short-term investments	39,700	41,650	101,228
Purchases of short-term investments	(35,272)	(31,206)	(28,894)
Capital expenditures	(36)	—	(450)
Payments for acquisition of intangible assets	(360)	(15,000)	—
Proceeds from sale of property and equipment	98	259	893
Net cash provided by (used in) investing activities	4,130	(4,297)	72,777
Financing activities
Net proceeds from term loan financing	—	19,950	19,542
Net proceeds from issuance of common stock from equity plans	1,964	1,049	2,124
Closing purchase price payment related to asset acquisition	(10,000)	—	—
Cost share payments to a collaboration partner	(3,605)	(2,632)	(15,116)
Net cash (used in) provided by financing activities	(11,641)	18,367	6,550
Net increase in cash and cash equivalents	23,960	8,327	5,569
Cash and cash equivalents at beginning of period	32,786	24,459	18,890
Cash and cash equivalents at end of period	$56,746	$32,786	$24,459
Supplemental disclosure of cash flow information
Interest paid	$7,039	$5,848	$2,495
Income taxes paid	331	—	—
Purchases of intangible asset included within accounts payable	—	—	15,000
Acquisition-related liabilities	5,000	—	—

** RIGEL PHARMACEUTICALS, INC.**

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.